SEC Contract Filing

Filing Date: 2016-11-10

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit1019302016.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
 <!-- Document created using Wdesk 1 -->
 <!-- Copyright 2016 Workiva -->
 <title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6FE1738EA0D5959D483F3756D479033D"></a></div><div><div style="line-height:130%;padding-bottom:10px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SECOND AMENDED AND RESTATED NANTOMICS EXCLUSIVE RESELLER AGREEMENT</font></div><div style="line-height:130%;padding-bottom:10px;text-align:justify;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Second Amended and Restated NantOmics Exclusive Reseller Agreement (this &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) is made as of September&#160;20, 2016, with an effective date as of June 19, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:11pt;">&#8221;), by and between NantOmics, LLC, a Delaware limited liability company (&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">NantOmics</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and NantHealth, Inc., a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">NantHealth</font><font style="font-family:inherit;font-size:11pt;">&#8221;). NantOmics and NantHealth are sometimes referred to herein as a &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Party</font><font style="font-family:inherit;font-size:11pt;">&#8221; and collectively as the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Parties</font><font style="font-family:inherit;font-size:11pt;">.&#8221;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RECITALS</font></div><div style="line-height:130%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, NantOmics has developed and makes available certain genomic and proteomic analysis and bioinformatics services;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, NantHealth and NantOmics are parties to that certain NantOmics Exclusive Reseller Agreement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Original Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;), effective as of June 19, 2015, under which NantHealth obtained the right to market and resell such services on an exclusive basis in the Commercial Field of Use (defined below);</font></div><div style="line-height:130%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, NantHealth and NantOmics amended and restated the Original Agreement pursuant to an Amended and Restated NantOmics Exclusive Reseller Agreement dated May&#160;9, 2016 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">First Restated Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to clarify certain terms of the Original Agreement;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, NantHealth and NantOmics wish to amend and restate the First Restated Agreement with the terms of this Agreement to clarify certain terms of the First Restated Agreement. </font></div><div style="line-height:130%;padding-bottom:10px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW, THEREFORE, for good and valuable consideration, including the mutual covenants and conditions herein contained, the Parties do hereby (a)&#160;amend, restate and replace the First Restated Agreement in its entirety and (b)&#160;otherwise agree as follows:</font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AGREEMENT</font></div><div style="line-height:130%;padding-bottom:10px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Definitions</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.<